Odyssey Therapeutics
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors
Odyssey Therapeutics; Nia Tatsis; Board of Directors; Vertex Pharmaceuticals; RIPK2 scaffolding inhibitor; autoimmune diseases; biopharmaceuticals; regulatory affairs; quality assurance